{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:02:49Z","timestamp":1771434169582,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04544-w","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:18:51Z","timestamp":1771222731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["How to manage patients with diabetes suffering from unstable blood glucose control due to insulin antibodies"],"prefix":"10.1007","volume":"91","author":[{"given":"M.","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-3452","authenticated-orcid":false,"given":"N.","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"4544_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1056\/NEJMra040832","volume":"352","author":"IB Hirsch","year":"2005","unstructured":"I.B. Hirsch, Insulin analogues. N. Engl. J. Med. 352, 174\u2013183 (2005). https:\/\/doi.org\/10.1056\/NEJMra040832","journal-title":"J. Med."},{"key":"4544_CR2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1210\/clinem\/dgab849","volume":"107","author":"MA Jarosinski","year":"2022","unstructured":"M.A. Jarosinski, Y.S. Chen, N. Varas, B. Dhayalan, D. Chatterjee, M.A. Weiss, New horizons: next-generation insulin analogues: structural principles and clinical goals. J. Clin. Endocrinol. Metab. 107, 909\u2013928 (2022). https:\/\/doi.org\/10.1056\/NEJMra040832","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4544_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2337\/diacare.12.9.641","volume":"12","author":"TWV Haeften","year":"1989","unstructured":"T.W.V. Haeften, Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care. 12, 641\u2013648 (1989). https:\/\/doi.org\/10.2337\/diacare.12.9.641","journal-title":"Diabetes Care"},{"key":"4544_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cca.2014.03.008","volume":"433","author":"N Hattori","year":"2014","unstructured":"N. Hattori, M.R. Duhita, A. Mukai, M. Matsueda, A. Shimatsu, Development of insulin antibodies and changes in titers over a long-term period in patients with type 2 diabetes. Clin. Chim. Acta. 433, 135\u2013138 (2014). https:\/\/doi.org\/10.1016\/j.cca.2014.03.008","journal-title":"Clin. Chim. Acta"},{"key":"4544_CR5","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.4239\/wjd.v15.i7.1489","volume":"15","author":"P Zhang","year":"2024","unstructured":"P. Zhang, Q. Jiang, B. Ding, R.N. Yan, Y. Hu, J.H. Ma, Association between glucose-lowering drugs and Circulating insulin antibodies induced by insulin therapy in patients with type 2 diabetes. World J. Diabetes. 15, 1489\u20131498 (2024). https:\/\/doi.org\/10.4239\/wjd.v15.i7.1489","journal-title":"World J. Diabetes"},{"key":"4544_CR6","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3390\/ijms26041730","volume":"26","author":"H Toft-Hansen","year":"2025","unstructured":"H. Toft-Hansen, C. Aniol-Nielsen, D. Elias, M. Dahlb\u00e4ck, P. Rossing, S. Sivalingam et al., Characterization of anti-insulin antibodies in type 1 and type 2 diabetes mellitus: clinical relevance. Int. J. Mol. Sci. 26, 1730 (2025). https:\/\/doi.org\/10.3390\/ijms26041730","journal-title":"Int. J. Mol. Sci."},{"key":"4544_CR7","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1530\/EC-17-0309","volume":"7","author":"X Hu","year":"2018","unstructured":"X. Hu, F. Chen, Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients. Endocr. Connect. 7, R47\u2013R55 (2018). https:\/\/doi.org\/10.1530\/EC-17-0309","journal-title":"Endocr. Connect."},{"key":"4544_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1210\/er.2007-0002","volume":"28","author":"SE Fineberg","year":"2007","unstructured":"S.E. Fineberg, T.T. Kawabata, D. Finco-Kent, R.J. Fountaine, G.L. Finch, A.S. Krasner, Immunological responses to exogenous insulin. Endocr. Rev. 28, 625\u2013652 (2007). https:\/\/doi.org\/10.1210\/er.2007-0002","journal-title":"Endocr. Rev."},{"key":"4544_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2337\/diacare.20.1.71","volume":"20","author":"JT Lahtela","year":"1997","unstructured":"J.T. Lahtela, M. Knip, R. Paul, J. Antonen, J. Salmi, Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. A case report. Diabetes Care. 20, 71\u201373 (1997). https:\/\/doi.org\/10.2337\/diacare.20.1.71","journal-title":"Diabetes Care"},{"key":"4544_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2169\/internalmedicine.39.143","volume":"39","author":"K Hara","year":"2000","unstructured":"K. Hara, K. Tobe, Y. Uchigataet, M. Nakazono, K. Yasuda, Y. Terauchi et al., Antibody-mediated insulin resistance treated by cessation of insulin administration. Intern. Med. 39, 143\u2013145 (2000). https:\/\/doi.org\/10.2169\/internalmedicine.39.143","journal-title":"Intern. Med."},{"key":"4544_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1464-5491.2008.02621.x","volume":"26","author":"JR Greenfield","year":"2009","unstructured":"J.R. Greenfield, A. Tuthill, M.A. Soos, R.K. Semple, D.J. Halsall, A. Chaudhry et al., Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy. Diabet. Med. 26, 79\u201382 (2009). https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02621.x","journal-title":"Diabet. Med."},{"key":"4544_CR12","doi-asserted-by":"publisher","first-page":"e15194","DOI":"10.1111\/dme.15194","volume":"40","author":"DS Church","year":"2023","unstructured":"D.S. Church, P. Barker, K.A. Burling, S.K. Shinwari, C. Kennedy, D. Smith et al., Diagnosis and treatment of anti-insulin antibody-mediated labile glycaemia in insulin-treated diabetes. Diabt Med. 40, e15194 (2023). https:\/\/doi.org\/10.1111\/dme.15194","journal-title":"Diabt Med."},{"key":"4544_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00000441-200505000-00007","volume":"329","author":"R Koyama","year":"2005","unstructured":"R. Koyama, K. Nakanishi, M. Kato, S. Yamashita, H. Kuwahara, H. Katori, Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin: treatment with double filtration plasmapheresis and prednisolone. Am. J. Med. Sci. 329, 259\u2013264 (2005). https:\/\/doi.org\/10.1097\/00000441-200505000-00007","journal-title":"Am. J. Med. Sci."},{"key":"4544_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ando.2015.10.004","volume":"76","author":"X Hu","year":"2015","unstructured":"X. Hu, X. Ma, X. Wang, X. Zhao, X. Xu, H. Gong et al., Insulin antibodies in patients with type 2 diabetic receiving Recombinant human insulin injection: A report of 12 cases. Ann. Endocrinol. (Paris). 76, 694\u2013697 (2015). https:\/\/doi.org\/10.1016\/j.ando.2015.10.004","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"4544_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12902-018-0326-3","volume":"19","author":"K Kaneko","year":"2019","unstructured":"K. Kaneko, C. Satake, T. Izumi, M. Tanaka, J. Yamamoto, Y. Asai et al., Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report. B M C Endocr. Disord. 19, 5 (2019). https:\/\/doi.org\/10.1186\/s12902-018-0326-3","journal-title":"B M C Endocr. Disord"},{"key":"4544_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1530\/EDM-16-0079","volume":"2016","author":"CT Su","year":"2016","unstructured":"C.T. Su, Y.C. Lin, Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog. Endocrinol. Diabetes Metab. Case Rep. 2016, 16\u20130079 (2016). https:\/\/doi.org\/10.1530\/EDM-16-0079","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"4544_CR17","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.2337\/dc16-2420","volume":"40","author":"L Marchand","year":"2017","unstructured":"L. Marchand, P. Luigi, J. Place, F. Dalla-Vale, A. Farret, E. Renard, Improvement of glucose control and reduction of hypoglycemia following intravenous immune globulins in a child with type 1 diabetes and high levels of insulin antibodies. Diabetes Care. 40, e69\u2013e70 (2017). https:\/\/doi.org\/10.2337\/dc16-2420","journal-title":"Diabetes Care"},{"key":"4544_CR18","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.2337\/dc16-1975","volume":"40","author":"JB Hao","year":"2017","unstructured":"J.B. Hao, S. Imam, P. Dar, M. Alfonso-Jaume, N. Elnagar, J.C. Jaume, Extreme insulin resistance from insulin antibodies (not insulin receptor antibodies) successfully treated with combination immunosuppressive therapy. Diabetes Care. 40, e19\u2013e20 (2017). https:\/\/doi.org\/10.2337\/dc16-1975","journal-title":"Diabetes Care"},{"key":"4544_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/1753-0407.12657","volume":"10","author":"Y Xiao","year":"2018","unstructured":"Y. Xiao, X. Li, C. Chao, G. Huang, W. Tang, S. Liu et al., Severe insulin resistance due to insulin antibodies. J. Diabetes. 10, 611\u2013613 (2018). https:\/\/doi.org\/10.1111\/1753-0407.12657","journal-title":"J. Diabetes"},{"key":"4544_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.aace.2021.03.004","volume":"7","author":"D Brooks","year":"2021","unstructured":"D. Brooks, P. Grewal, I. Baine, S.A. Arinsburg, S. Maximos, N.A. Shah, Mycophenolate mofetil and plasmapheresis: a treatment option for severe insulin resistance caused by insulin antibodies. A.A.C.E. Clin. Case Rep. 7, 307\u2013309 (2021). https:\/\/doi.org\/10.1016\/j.aace.2021.03.004","journal-title":"Case Rep."},{"key":"4544_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1089\/dia.2020.0438","volume":"23","author":"M Ahmed","year":"2021","unstructured":"M. Ahmed, M.V.S. Subbalaxmi, B. Anne, S. Deme, Recurrent diabetic ketoacidosis and extreme insulin resistance due to anti-insulin antibodies: response to immunosuppression and plasma exchange. Diabetes Technol. Ther. 23, 227\u2013229 (2021). https:\/\/doi.org\/10.1089\/dia.2020.0438","journal-title":"Diabetes Technol. Ther."},{"key":"4544_CR22","doi-asserted-by":"publisher","unstructured":"T. Kato, K. Iizuka, H. Niwa, J. Takeda, Liraglutide improved glycaemic instability in a patient with diabetes with insulin antibodies. B.M.J. Case rep 216 Bcr 2016216028 (2016). https:\/\/doi.org\/10.1136\/bcr-2016-216028","DOI":"10.1136\/bcr-2016-216028"},{"key":"4544_CR23","doi-asserted-by":"publisher","unstructured":"A. Hayashi, K. Takano, S. Kawai, M. Shichiri, SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies. Endocr. J. 2016;63:187\u2013191 (2016). https:\/\/doi.org\/10.1507\/endocrj.EJ15-0523","DOI":"10.1507\/endocrj.EJ15-0523"},{"key":"4544_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/07315724.2014.976673","volume":"35","author":"R Li","year":"2016","unstructured":"R. Li, J. Mao, K. Yu, L. Wang, M. Hu, L. Xu, Medical nutrition therapy is effective in the management of hypoglycemia caused by insulin antibodies: A case report and literature review. J. Am. Coll. Nutr. 35, 86\u201390 (2016). https:\/\/doi.org\/10.1080\/07315724.2014.976673","journal-title":"J. Am. Coll. Nutr."},{"key":"4544_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/1932296818805074","volume":"13","author":"JL Knopp","year":"2019","unstructured":"J.L. Knopp, L. Holder-Pearson, J.G. Chase, Insulin units and conversion factors: a story of truth, boots, and faster half-truths. J. Diabetes Sci. Technol. 13, 597\u2013600 (2019). https:\/\/doi.org\/10.1177\/1932296818805074","journal-title":"J. Diabetes Sci. Technol."},{"key":"4544_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2337\/diab.26.1.22","volume":"26","author":"H Kuzuya","year":"1977","unstructured":"H. Kuzuya, P.M. Blix, D.L. Horwitz, D.F. Steiner, A.H. Rubenstein, Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes. 26, 22\u201329 (1977). https:\/\/doi.org\/10.2337\/diab.26.1.22","journal-title":"Diabetes"},{"key":"4544_CR27","doi-asserted-by":"publisher","unstructured":"A.C. Landaburu, M. Pomares, A. Avalos, S. Lapertosa, G. Frechtel, E. Poskus, Use of cross-reactivity immunoassay to orient insulin replacement in diabetic patients with high levels of insulin antibodies. MethodsX 3, 502\u2013507 (2016). https:\/\/doi.org\/10.1016\/j.mex.2016.08.003. eCollection 2016","DOI":"10.1016\/j.mex.2016.08.003"},{"key":"4544_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13256-019-1989-8","volume":"13","author":"S Kobayashi","year":"2019","unstructured":"S. Kobayashi, H. Amano, Y. Kawaguchi, T. Yokoo, A novel treatment of hyperinsulinemic hypoglycemia induced by insulin antibodies with alkali administration: a case report. J. Med. Case Rep. 13, 79 (2019)","journal-title":"J. Med. Case Rep."},{"key":"4544_CR29","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1002\/ajh.26882","volume":"98","author":"AG Kulasekararaj","year":"2023","unstructured":"A.G. Kulasekararaj, I. Lazana, Paroxysmal nocturnal hemoglobinuria: where are we going. Am. J. Hematol. 98, S33\u2013S43 (2023). https:\/\/doi.org\/10.1002\/ajh.26882","journal-title":"Am. J. Hematol."},{"key":"4544_CR30","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.bbapap.2014.08.003","volume":"1844","author":"T Igawa","year":"2014","unstructured":"T. Igawa, F. Mimoto, K. Hattori, pH-dependent antigen-binding antibodies as a novel therapeutic modality. Biochim. Biophys. Acta. 1844, 1943\u20131950 (2014). https:\/\/doi.org\/10.1016\/j.bbapap.2014.08.003","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04544-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04544-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04544-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:06:11Z","timestamp":1771430771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04544-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4544"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04544-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Research Ethics Review Board of the Kansai Medical University (2024040).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"71"}}